CDK4/6 inhibition in combination with aromatase inhibitors or ER modulators (such as letrozole and fulvestrant) is currently emerging as the standard of care for HR+ breast cancers due to improved patient survival in clinical trials (Im et al., 2019; Slamon et al., 2020). Here, ESR1 is linked to breast cancer.